T-E Meds Presents TE-1146 NAMs Research in Collaboration with Anivance AI at World ADC

T-E Meds, a subsidiary of T-E Pharma, recently presented preclinical research progress on its ADC candidate TE-1146 at the World ADC conference in San Diego, USA.

Dr. Hsing-Mao Chu, CEO of T-E Pharma, shared findings including selected safety assessment studies conducted in collaboration with Anivance AI using New Approach Methodologies (NAMs), human cell models, and organ-on-a-chip technologies.

These studies covered several areas, including the heart, liver, kidneys, and bone marrow, highlighting the company’s strategy of integrating innovative research approaches to build evidence supporting the efficacy and safety of its drug candidates.